-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is the 22nd issue of the "Firestone Creates Industrial Brain" financing bulletin.
Source: Flint Creation Database
[Financing Overview] This week, there were 30 investment and financing incidents in the medical and health sector across the country, with a cumulative amount of more than 2.
Source: Flint Creation Database
[Geographical distribution of financing] This week's financing projects are mainly distributed in Guangdong Province (9 cases) and Beijing (6 cases)
Source: Flint Creation Database
[Financing Amount Distribution] A total of 30 projects received investment this week, with a cumulative amount exceeding 2.
Source: Flint Creation Database
[The most popular areas for investors] This week, other areas attracted the most money, with the financing amount exceeding 1.
Source: Flint Creation Database
The most noteworthy financing project
1.
This round of financing will be used to further promote the innovative research and development, registration declaration and clinical services of products such as tumor panel genetic testing and early tumor screening, as well as in-depth cooperation with innovative pharmaceutical companies in the tumor field on the collaborative development of new drugs
This round of financing was jointly led by Haida Investment and Shenzhen Venture Capital.
The capital increase is to meet the capital needs of the company's wholly-owned subsidiary Beijing Yihong for the business development.
List of financing events this week
Active investment institutions in the healthcare industry this week: Matrix Partners China, Tongchuang Weiye (3 cases each), Sequoia Capital China, Sherpa Investment, Innovation Workshop, Guoxin Health, Hillhouse Ventures (2 cases each)
